These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32385732)

  • 1. Quality by Design-Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®.
    Zhang E; Xie L; Qin P; Lu L; Xu Y; Gao W; Wang L; Xie MH; Jiang W; Liu S
    AAPS J; 2020 May; 22(3):69. PubMed ID: 32385732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®.
    Magnenat L; Palmese A; Fremaux C; D'Amici F; Terlizzese M; Rossi M; Chevalet L
    MAbs; 2017 Jan; 9(1):127-139. PubMed ID: 27854156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QbD-guided pharmaceutical development of Pembrolizumab biosimilar candidate PSG-024 propelled to industry meeting primary requirements of comparability to Keytruda®.
    Jaffar-Aghaei M; Khanipour F; Maghsoudi A; Sarvestani R; Mohammadian M; Maleki M; Havasi F; Rahmani H; Karagah AH; Kazemali MR
    Eur J Pharm Sci; 2022 Jun; 173():106171. PubMed ID: 35378209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physicochemical and Functional Characterization of HS016, a Biosimilar of Adalimumab (Humira).
    Gao D; Nie L; Yuan J; Hu F; Wu Z; Lin Q; Wang H
    J Pharm Sci; 2022 Apr; 111(4):1142-1151. PubMed ID: 34863972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demonstration of functional similarity of a biosimilar adalimumab SB5 to Humira
    Lee JJ; Yang J; Lee C; Moon Y; Ahn S; Yang J
    Biologicals; 2019 Mar; 58():7-15. PubMed ID: 30744947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab.
    Liu J; Eris T; Li C; Cao S; Kuhns S
    BioDrugs; 2016 Aug; 30(4):321-38. PubMed ID: 27461107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab.
    Lee N; Lee JJ; Yang H; Baek S; Kim S; Kim S; Lee T; Song D; Park G
    MAbs; 2019 Jan; 11(1):129-144. PubMed ID: 30296198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scientific and statistical considerations in evaluating the analytical similarity of ABP 501 to adalimumab.
    Sivendran R; Ramírez J; Ramchandani M; Liu J
    Immunotherapy; 2018 Aug; 10(11):1011-1021. PubMed ID: 30071739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double-blind, parallel-controlled, phase 1 study.
    Zhang H; Wu M; Sun J; Zhu X; Li C; Ding Y; Zhang X; Chai K; Li X
    Pharmacol Res Perspect; 2021 Apr; 9(2):e00733. PubMed ID: 33682358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab.
    Schreiber S; Yamamoto K; Muniz R; Iwura T
    Pharmacol Res Perspect; 2020 Jun; 8(3):e00604. PubMed ID: 32500668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira.
    McClellan JE; Ómarsdóttir S; Roy N; Berger V; Michel C; Berti F
    Ther Adv Chronic Dis; 2024; 15():20406223231223286. PubMed ID: 38250743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®).
    Kwon JC; Kwon OH; Jeong RU; Kim N; Song S; Choi I; Lee J; Horiuchi T
    Anim Cells Syst (Seoul); 2021; 25(3):182-194. PubMed ID: 34262661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of high mannose levels in N-linked glycosylation through cell culture process conditions to increase antibody-dependent cell-mediated cytotoxicity activity for an antibody biosimilar.
    Rameez S; Gowtham YK; Nayar G; Mostafa SS
    Biotechnol Prog; 2021 Sep; 37(5):e3176. PubMed ID: 34021724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-attribute method (MAM) to assess analytical comparability of adalimumab biosimilars.
    Millán-Martín S; Jakes C; Carillo S; Bones J
    J Pharm Biomed Anal; 2023 Sep; 234():115543. PubMed ID: 37385093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin
    Xie L; Zhang E; Xu Y; Gao W; Wang L; Xie MH; Qin P; Lu L; Li S; Shen P; Jiang W; Liu S
    BioDrugs; 2020 Jun; 34(3):363-379. PubMed ID: 32072477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity.
    Kang J; Eudy-Byrne RJ; Mondick J; Knebel W; Jayadeva G; Liesenfeld KH
    Br J Clin Pharmacol; 2020 Nov; 86(11):2274-2285. PubMed ID: 32363771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cation exchange chromatography on a monodisperse 3 µm particle enables extensive analytical similarity assessment of biosimilars.
    Füssl F; Millán-Martín S; Bones J; Carillo S
    J Pharm Biomed Anal; 2023 Sep; 234():115534. PubMed ID: 37343453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new CHO (Chinese hamster ovary)-derived cell line expressing anti-TNFα monoclonal antibody with biosimilar potential.
    Luchese MD; Lopes Dos Santos M; Garbuio A; Targino RC; Mansueli CP; Tsuruta LR; Quintilio W; Moro AM
    Immunol Res; 2018 Jun; 66(3):392-405. PubMed ID: 29855993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods.
    von Richter O; Lemke L; Haliduola H; Fuhr R; Koernicke T; Schuck E; Velinova M; Skerjanec A; Poetzl J; Jauch-Lembach J
    Expert Opin Biol Ther; 2019 Oct; 19(10):1075-1083. PubMed ID: 30698045
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses.
    Lee J; Kang HA; Bae JS; Kim KD; Lee KH; Lim KJ; Choo MJ; Chang SJ
    MAbs; 2018; 10(4):547-571. PubMed ID: 29482416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.